Lantheus Holdings, Inc. (LNTH)
- Previous Close
108.56 - Open
108.74 - Bid 109.81 x 600
- Ask 110.35 x 800
- Day's Range
107.61 - 110.47 - 52 Week Range
50.20 - 126.89 - Volume
984,922 - Avg. Volume
1,079,874 - Market Cap (intraday)
7.641B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
18.10 - EPS (TTM)
6.08 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
144.55
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
www.lantheus.com834
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LNTH
View MorePerformance Overview: LNTH
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LNTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LNTH
View MoreValuation Measures
Market Cap
7.65B
Enterprise Value
7.51B
Trailing P/E
18.11
Forward P/E
1.48
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.39
Price/Book (mrq)
7.45
Enterprise Value/Revenue
5.22
Enterprise Value/EBITDA
11.85
Financial Highlights
Profitability and Income Statement
Profit Margin
29.80%
Return on Assets (ttm)
17.41%
Return on Equity (ttm)
54.26%
Revenue (ttm)
1.44B
Net Income Avi to Common (ttm)
428.48M
Diluted EPS (ttm)
6.08
Balance Sheet and Cash Flow
Total Cash (mrq)
757.02M
Total Debt/Equity (mrq)
60.41%
Levered Free Cash Flow (ttm)
263.3M